The discovery of the Archaea and the proposal of the three-domains ‘universal’ tree, based on ribosomal RNA and core genes mainly involved in protein translation, catalysed new ideas for cellular evolution and eukaryotic origins. However, accumulating evidence suggests that the three-domains tree may be incorrect: evolutionary trees made using newer methods place eukaryotic core genes within the Archaea, supporting hypotheses in which an archaeon participated in eukaryotic origins by founding the host lineage for the mitochondrial endosymbiont. These results provide support for only two primary domains of life—Archaea and Bacteria—because eukaryotes arose through partnership between them.Apparently, even evolutionary phylogenetics follows the ancient, familiar, and inviolable principle that two's company, but three's a crowd.
Sunday, December 15, 2013
Life Gets Simpler
In a new article, published in Nature on December 12, 2013, Williams et al. present evidence supporting the "Eocyte hypothesis" that the Tree of Life has only two branches (Bacteria and Archaea), not three (Bacteria, Archaea, and Eukaryota). Their article, entitled "An archaeal origin of eukaryotes supports only two primary domains of life," situates the Eukaryota (organisms with cellular nuclei), for the most part, within the Archaea. Here is the article's abstract:
Wednesday, December 11, 2013
Leiter Side Of Religion
Philosopher, legal scholar, and blogger, Professor Brian Leiter, recently published a book on the law and philosophy of religion and conscience, entitled Why Tolerate Religion? Here is a video of his November 19, 2013, lecture, "Why Tolerate Religion?," at the University of Chicago:
Here is a description of his book by its publisher, Princeton University Press:
Here is a description of his book by its publisher, Princeton University Press:
In Why Tolerate Religion?, Brian Leiter argues that the reasons have nothing to do with religion, and that Western democracies are wrong to single out religious liberty for special legal protections. He offers new insights into what makes a claim of conscience distinctively "religious," and draws on a wealth of examples from America, Europe, and elsewhere to highlight the important issues at stake. With philosophical acuity, legal insight, and wry humor, Leiter shows why our reasons for tolerating religion are not specific to religion but apply to all claims of conscience, and why a government committed to liberty of conscience is not required by the principle of toleration to grant exemptions to laws that promote the general welfare.As modern societies become ever more diverse along the axes of religion and conscience, the need for incisive analysis of how the law should treat - and should or should not privilege - religious belief grows ever more urgent. Leiter is an important voice in this debate.
Tuesday, December 10, 2013
Georges Cuvier - Father Of Extinction
The December 16, 2013, issue of The New Yorker has a fascinating article on extinction by Elizabeth Kolbert. It chronicles the "discovery" of extinction by the French biologist Jean-Léopold-Nicholas-Frédéric "Georges" Cuvier. Although extinction is now a distressingly common concept, in large part due to the current anthropogenic mass extinction event, the article discusses just how controversial an idea extinction was in the 18th Century.
Friday, December 6, 2013
Pseudopreneurship
Entrepreneurship is all the rage these days. Everyone seems to want to found a company, though considerable empirical evidence suggest that fewer and fewer people actually do so. In fact, the number of people claiming to have been entrepreneurs probably vastly exceeds the actual number of company founders. Carefully scrutinize many biographies, webpages, and curricula vitae, and one is amazed by how flexible the definition of "entrepreneur" seems to have become. This phenomenon demands a new moniker: "pseudopreneur." As I conceive it, a pseudopreneur is anyone whose claim to have founded a company is specious, silly, or just plain dishonest. Pseudopreneurs are legion. Spot them if you can.
Thursday, December 5, 2013
Graecide: Life On The Vineyard
One of the best shows on radio, This American Life, recently rebroadcast a tragic story about the police killing of Tom The Turkey, a local avian celebrity on Martha's Vineyard. I will not reveal the identities of the two wonderful people who tried to save Tom from the police because they are very close friends of mine. I applaud their brave efforts to defend Tom. Listen to Murder Most Fowl.
Saturday, November 30, 2013
Corny Science
The journal Nature reported on November 28, 2013, the retraction of a published scientific article claiming that laboratory rats fed genetically-modified ("GM") maize suffered substantial health problems. As the journal reported,
This retraction, by Food and Chemical Toxicology, is not the first. In 2007, I published an article, entitled "Intellectual Property as the Third Dimension of GMO Regulation," that discusses similar previous GM publication shlamazels (available for free download here). Disputes over food are often primal in character. They have led to war, revolution, famine, and disease. People behave from instinct when their access to healthy food appears threatened. For this reason, ensuring that information about food is derived from reliable science is vital. Publication of flawed food science is not merely unpalatable for peer review journals, it can cause painful political indigestion.
Bowing to scientists' near-universal scorn, the journal Food and Chemical Toxicology today fulfilled its threat to retract a controversial paper claiming that a genetically modified (GM) maize causes serious disease in rats, after the authors refused to withdraw it.Elsevier, the publisher of Food and Chemical Toxicology, explained its decision to retract the article as follows:
there is a legitimate cause for concern regarding both the number of animals in each study group and the particular strain selected. The low number of animals had been identified as a cause for concern during the initial review process, but the peer review decision ultimately weighed that the work still had merit despite this limitation. A more in-depth look at the raw data revealed that no definitive conclusions can be reached with this small sample size regarding the role of either NK603 or glyphosate in regards to overall mortality or tumor incidence. Given the known high incidence of tumors in the Sprague-Dawley rat, normal variability cannot be excluded as the cause of the higher mortality and incidence observed in the treated groups.There are interesting times - sensu the oft-cited, but apparently apocryphal, Chinese curse - for the science and public opinion of GM food. While robust scientific evidence that GM food causes harm to humans remains elusive, a vocal opposition maintains that GM food is unhealthy.
This retraction, by Food and Chemical Toxicology, is not the first. In 2007, I published an article, entitled "Intellectual Property as the Third Dimension of GMO Regulation," that discusses similar previous GM publication shlamazels (available for free download here). Disputes over food are often primal in character. They have led to war, revolution, famine, and disease. People behave from instinct when their access to healthy food appears threatened. For this reason, ensuring that information about food is derived from reliable science is vital. Publication of flawed food science is not merely unpalatable for peer review journals, it can cause painful political indigestion.
there
is a legitimate cause for concern regarding both the number of animals
in each study group and the particular strain selected. The low number
of animals had been identified as a cause for concern during the initial
review process, but the peer review decision ultimately weighed that
the work still had merit despite this limitation. A more in-depth look
at the raw data revealed that no definitive conclusions can be reached
with this small sample size regarding the role of either NK603 or
glyphosate in regards to overall mortality or tumor incidence. Given the
known high incidence of tumors in the Sprague-Dawley rat, normal
variability cannot be excluded as the cause of the higher mortality and
incidence observed in the treated groups. - See more at:
http://www.elsevier.com/about/p
there
is a legitimate cause for concern regarding both the number of animals
in each study group and the particular strain selected. The low number
of animals had been identified as a cause for concern during the initial
review process, but the peer review decision ultimately weighed that
the work still had merit despite this limitation. A more in-depth look
at the raw data revealed that no definitive conclusions can be reached
with this small sample size regarding the role of either NK603 or
glyphosate in regards to overall mortality or tumor incidence. Given the
known high incidence of tumors in the Sprague-Dawley rat, normal
variability cannot be excluded as the cause of the higher mortality and
incidence observed in the treated groups. - See more at:
http://www.elsevier.com/about/press-releases/research-and-journals/elsevier-announces-article-retraction-from-journal-food-and-chemical-toxicology#sthash.0DEVUvqe.dpuf
there
is a legitimate cause for concern regarding both the number of animals
in each study group and the particular strain selected. The low number
of animals had been identified as a cause for concern during the initial
review process, but the peer review decision ultimately weighed that
the work still had merit despite this limitation. A more in-depth look
at the raw data revealed that no definitive conclusions can be reached
with this small sample size regarding the role of either NK603 or
glyphosate in regards to overall mortality or tumor incidence. Given the
known high incidence of tumors in the Sprague-Dawley rat, normal
variability cannot be excluded as the cause of the higher mortality and
incidence observed in the treated groups. - See more at:
http://www.elsevier.com/about/press-releases/research-and-journals/elsevier-announces-article-retraction-from-journal-food-and-chemical-toxicology#sthash.0DEVUvqe.dpuf
there
is a legitimate cause for concern regarding both the number of animals
in each study group and the particular strain selected. The low number
of animals had been identified as a cause for concern during the initial
review process, but the peer review decision ultimately weighed that
the work still had merit despite this limitation. A more in-depth look
at the raw data revealed that no definitive conclusions can be reached
with this small sample size regarding the role of either NK603 or
glyphosate in regards to overall mortality or tumor incidence. Given the
known high incidence of tumors in the Sprague-Dawley rat, normal
variability cannot be excluded as the cause of the higher mortality and
incidence observed in the treated groups. - See more at:
http://www.elsevier.com/about/press-releases/research-and-journals/elsevier-announces-article-retraction-from-journal-food-and-chemical-toxicology#sthash.0DEVUvqe.dpuf
there
is a legitimate cause for concern regarding both the number of animals
in each study group and the particular strain selected. The low number
of animals had been identified as a cause for concern during the initial
review process, but the peer review decision ultimately weighed that
the work still had merit despite this limitation. A more in-depth look
at the raw data revealed that no definitive conclusions can be reached
with this small sample size regarding the role of either NK603 or
glyphosate in regards to overall mortality or tumor incidence. Given the
known high incidence of tumors in the Sprague-Dawley rat, normal
variability cannot be excluded as the cause of the higher mortality and
incidence observed in the treated groups. - See more at:
http://www.elsevier.com/about/press-releases/research-and-journals/elsevier-announces-article-retraction-from-journal-food-and-chemical-toxicology#sthash.0DEVUvqe.dpuf
Thursday, November 28, 2013
Designs On Thanksgiving
The wonderful design patent blog, The Ordinary Observer, has an entertaining and enlightening discussion of proper apportionment of damages in design patent infringement cases. Just in time for American Thanksgiving, enjoy "The Turducken Problem."
Lexvivo wishes everyone Happy Thanksgiving!
Lexvivo wishes everyone Happy Thanksgiving!
Wednesday, November 27, 2013
The Evil Twins Debating
The University of Richmond School of Law's Seventh Annual "Evil Twins Debate" was held on November 15, 2013. Professor Mark Janis of the Indiana University Maurer School of Law and I (Professor Andrew Torrance of the University of Kansas School of Law) debated the topic "Design Patents: Great Idea, or Greatest Idea?" For the sake of argument, I represented the Greatest Idea position while Mark argued in favor of the Great Idea side. Here is the video of the Evil Twins Debate on the University of Richmond School of Law YouTube channel:
Intellectual property experts, Professor Jim Gibson and Professor Chris Cotropia, deserve immense credit for making the Evil Twins Debate the wonderful institution it has become. Thanks very much, Jim and Chris, for inviting me to be a 2013 Evil Twin.
Intellectual property experts, Professor Jim Gibson and Professor Chris Cotropia, deserve immense credit for making the Evil Twins Debate the wonderful institution it has become. Thanks very much, Jim and Chris, for inviting me to be a 2013 Evil Twin.
Tuesday, November 26, 2013
Gene Choices & Choice Genes
The United States Patent and Trademark Office ("USPTO") issued United States Patent Number 8,543,339 to 23andMe, Inc. on September 24, 2013. The patent is entitled "Gamete Donor Selection Based On Genetic Calculations." Here is the abstract:
Gamete donor selection includes receiving a specification including a phenotype of interest, receiving a genotype of a recipient and a plurality of genotypes of a respective plurality of donors, determining statistical information pertaining to the phenotype of interest based at least in part on different pairings of the genotype of the recipient and a genotype of a donor in the plurality of donors, and identifying a preferred donor among the plurality of donors, based at least in part on the statistical information determined.Here is Claim 1 of the patent, as issued by the USPTO:
A system for gamete donor selection comprising: one or more processors configured to: receive a specification including a phenotype of interest that can be present in a hypothetical offspring; receive a genotype of a recipient and a plurality of genotypes of a respective plurality of donors; determine statistical information including probabilities of observing the phenotype of interest resulting from different combinations of the genotype of the recipient and genotypes of the plurality of donors; and identify a preferred donor among the plurality of donors, based at least in part on an evaluation of the statistical information determined, including: to compare the probabilities of observing the phenotype of interest resulting from different combinations of the genotype of the recipient and the genotypes of the plurality of donors to identify the preferred donor; and a memory coupled to the processor, configured to provide the processor with instructions.Assuming that 23andMe develops this concept into a commercial service, choosing the genetic traits of one's baby may soon be as easy as a few mouse-clicks and the swipe of a credit card. As I suggested in a 2008 article entitled "Patenting Human Evolution" (freely available here) and a 2009 article entitled "Open and Proprietary Biological Innovation in Human Genetic Enhancement" (freely available here), patents may soon be a selective force that helps drive human evolution. Perhaps this patent is a harbinger.
Monday, November 25, 2013
23andFDA
Knowledge of the human genome promises much to humanity. One common suggestion is that sequencing a person's genome will unlock powerful opportunities for diagnosis and therapy. A leader in the commercial market for human genomics is Google's neighbor, 23andMe, Inc., of Mountain View, California. It fashions itself "The leading health and ancestry DNA service." The Food and Drug Administration ("FDA") appears to think that 23andme has moved its services into the market prematurely. In a "WARNING LETTER" sent to the company on November 22, 2013, the FDA states that it has yet to approve 23andme's product, which the agency characterizes as
Regardless of the outcome of this particular FDA enforcement action, human genomics is certain to play an acceleratingly-important role in human health. As the avid Tudorian, Allison Plowden, once wrote, "The laws of genetics apply even if you refuse to learn them."
a device within the meaning of section 201(h) of the [Food, Drug and Cosmetic] Act ["FDCA"], 21 U.S.C. 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body.In its letter, the FDA orders 23andme to take its product off the market immediately:
23andMe must immediately discontinue marketing the PGS until such time as it receives FDA marketing authorization for the device. The PGS is in class III under section 513(f) of the FD&C Act, 21 U.S.C. 360c(f). Because there is no approved application for premarket approval in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g), the PGS is adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B). Additionally, the PGS is misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because notice or other information respecting the device was not provided to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).This federal regulatory enforcement action is sure to galvanize the human genomics industry into action. One possibility is to spur efforts to comply better with the FDCA. Another is that 23andme will challenge the FDA's allegations, perhaps by disputing whether the FDCA does, in fact, apply to genomics testing. It is not a foregone conclusion that the federal courts will side with the FDA, even though they do tend to give federal agency decisions considerable deference.
Regardless of the outcome of this particular FDA enforcement action, human genomics is certain to play an acceleratingly-important role in human health. As the avid Tudorian, Allison Plowden, once wrote, "The laws of genetics apply even if you refuse to learn them."
Subscribe to:
Posts (Atom)